Loading clinical trials...
Loading clinical trials...
A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis
Conditions
Interventions
Placebo
Relamorelin
Locations
240
United States
North Alabama Research Center, LLC
Athens, Alabama, United States
Synexus Clinical Research US - Simon Williamson Clinic
Birmingham, Alabama, United States
G & L Research, LLC
Foley, Alabama, United States
Alabama Medical Group, PC
Mobile, Alabama, United States
Synexus Clinical Research US, Inc.
Tucson, Arizona, United States
Applied Research Center of Arkansas
Little Rock, Arkansas, United States
Start Date
February 16, 2018
Primary Completion Date
July 16, 2020
Completion Date
July 16, 2020
Last Updated
August 6, 2021
NCT07224321
NCT07536516
NCT07340320
NCT06513026
NCT07222137
NCT07232537
Lead Sponsor
Allergan
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions